Soleno Therapeutics (SLNO) EBIAT (2013 - 2026)
Soleno Therapeutics (SLNO) reported EBIAT of $31.4 million for Q1 2026, up 171.68% year-over-year from $11.5 million in Q1 2025, and down 27.68% on a QoQ basis from $43.4 million in Q4 2025.
Soleno Therapeutics (SLNO) has 14 years of EBIAT data on file, last reported at $31.4 million in Q1 2026.
- Quarterly EBIAT rose 171.68% year-over-year to $31.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.1 million (up 148.47% YoY) and the FY2025 annual result came in at $20.9 million, up 111.88% from the prior year.
- EBIAT declined to $31.4 million in Q1 2026 per SLNO's latest filing, from $43.4 million in the prior quarter.
- Across five years, EBIAT topped out at $43.4 million in Q4 2025 and bottomed at -$76.6 million in Q3 2024.
- The 5-year median for EBIAT is -$8.4 million (2023), against an average of -$11.0 million.
- The widest annual swing landed in 2024, when EBIAT sank 605.42%; it then soared 177.51% in 2025.
- Tracing SLNO's EBIAT over 5 years: stood at -$5.5 million in 2022, then tumbled by 105.91% to -$11.3 million in 2023, then plunged by 395.59% to -$56.0 million in 2024, then soared by 177.51% to $43.4 million in 2025, then decreased by 27.68% to $31.4 million in 2026.
- Per Business Quant, the three latest SLNO EBIAT figures stand at $31.4 million (Q1 2026), $43.4 million (Q4 2025), and $26.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.38 Mn |
| Dec 31, 2025 | 43.39 Mn |
| Sep 30, 2025 | 26.01 Mn |
| Jun 30, 2025 | -4.71 Mn |
| Mar 31, 2025 | -43.77 Mn |
| Dec 31, 2024 | -55.98 Mn |
| Sep 30, 2024 | -76.62 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Mar 31, 2024 | -21.40 Mn |
| Dec 31, 2023 | -11.30 Mn |
| Sep 30, 2023 | -10.86 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -8.36 Mn |
| Dec 31, 2022 | -5.49 Mn |
| Sep 30, 2022 | -6.13 Mn |
| Jun 30, 2022 | -6.73 Mn |
| Mar 31, 2022 | -5.72 Mn |
| Dec 31, 2021 | -2.83 Mn |
| Sep 30, 2021 | -8.14 Mn |
| Jun 30, 2021 | -10.99 Mn |
| Mar 31, 2021 | -8.95 Mn |
| Dec 31, 2020 | -2.85 Mn |
| Sep 30, 2020 | -8.55 Mn |
| Jun 30, 2020 | -7.38 Mn |
| Mar 31, 2020 | -5.86 Mn |
| Dec 31, 2019 | -14.63 Mn |
| Sep 30, 2019 | 889,000.00 |
| Jun 30, 2019 | -10.01 Mn |
| Mar 31, 2019 | -7.03 Mn |
| Dec 31, 2018 | 263,000.00 |
| Sep 30, 2018 | -2.31 Mn |
| Jun 30, 2018 | -7.06 Mn |
| Mar 31, 2018 | -3.80 Mn |
| Dec 31, 2017 | -7.79 Mn |
| Sep 30, 2017 | -2.49 Mn |
| Jun 30, 2017 | -3.06 Mn |
| Mar 31, 2017 | -2.05 Mn |
| Dec 31, 2016 | -1.42 Mn |
| Sep 30, 2016 | -1.78 Mn |
| Jun 30, 2016 | -3.51 Mn |
| Mar 31, 2016 | -3.19 Mn |
| Dec 31, 2015 | -2.84 Mn |
| Sep 30, 2015 | -3.29 Mn |
| Jun 30, 2015 | 1.88 Mn |
| Mar 31, 2015 | -11.65 Mn |
| Dec 31, 2014 | -7.22 Mn |
| Sep 30, 2014 | -2.39 Mn |
| Jun 30, 2014 | -2.79 Mn |
| Mar 31, 2014 | -834,000.00 |
| Dec 31, 2013 | -974,243.00 |
| Sep 30, 2013 | -1.59 Mn |